2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMORecruiting
Study Objectives:The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK),pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients withthrombotic microangiopathies (TMA) following…